Research Progress in microRNA-Based Therapy for Gastric Cancer

Abstract: Gastric cancer (GC) is one of the leading causes of tumor-related mortality. In addition to surgery and endoscopic resection, systemic therapy remains the main treatment option for GC, especially for advanced-stage disease and for cases not suitable for surgical therapy. Hence, improving the efficacy of systemic therapy is still an urgent problem to overcome. In the past decade, the essential roles of microRNAs (miRNAs) in tumor treatment have been increasingly recognized. In particular, miRNAs were recently shown to reverse the resistance to chemotherapy drugs such as 5-fluorouracil, cisplatin, and doxorubicin. Synthesized nanoparticles loaded with mimics or inhibitors of miRNAs can directly target tumor cells to suppress their growth. Moreover, exosomes may serve as promising safe carriers for mimics or inhibitors of miRNAs to treat GC. Some miRNAs have also been shown to play roles in the mechanism of action of other anti-tumor drugs. Therefore, in this review, we highlight the research progress on microRNA-based therapy in GC and discuss the challenges and prospects associated with this strategy. We believe that microRNA-based therapy has the potential to offer a clinical benefit to GC patients, and this review would contribute to and motivate further research to promote this field toward this ultimate goal.

Keywords: therapeutics, drug resistance, nanoparticles, treatment mechanism

Introduction

Gastric cancer (GC) has an extremely high rate of mortality and is ranked as one of the leading causes of cancer-related death worldwide.\(^1,2\) Besides adequate surgical resection and endoscopic resection, adjuvant and neoadjuvant therapies are generally used to improve the disease-free survival and overall survival of patients with GC.\(^3,4\) However, it remains an important challenge to develop more effective systematic treatments for GC, especially for patients with inoperable disease at diagnosis or recurrent disease after resection. The development of resistance to standard chemotherapy drugs such as 5-fluorouracil (5-FU), cisplatin, and doxorubicin has been the main cause of chemotherapy failure. Moreover, first-line targeted therapies such as trastuzumab and ramucirumab are not suitable for the majority of patients with GC.\(^5,6\) Hence, extensive research effort has focused on solving this current treatment challenge by gaining a better understanding of the underlying pathogenic mechanisms and conducting preclinical studies for ultimate clinical application.

In the last decade, exploration of the roles of miRNAs in carcinogenesis, treatment response, and as potential therapeutic targets has attracted widespread attention, with substantial progress made in better understanding mechanisms.\(^7\) On the basis of mechanism-related studies, there has been increasing effort made to...
further explore the practical applications of these fundamental findings, which have revealed the essential roles of microRNAs in tumor therapy. 

Moreover, reduced miR-6785-5p, suggesting that they warrant further attention. A role of miR-31 in chemosensitivity was indeed, these studies have led to a major advance in the clinical application of miRNAs. Moreover, these findings suggested that in addition to their function as biomarkers, miRNAs can also play roles in the treatment of tumors. Nevertheless, despite these many important findings, there has been no study that summarizes these recent advances in microRNA-based therapy for GC.

Therefore, in this review, we mainly focus on the advances in microRNA-based therapies for GC, including chemotherapy, targeted therapy, tumor immunotherapy, and others. In particular, we highlight the key miRNAs reported to affect the actions of commonly used chemotherapy drugs, which will facilitate further research on drug resistance. Moreover, the listed carriers that loaded mimics or inhibitors of miRNAs can emphasize the promising applications of anti-tumor miRNAs in targeted therapy and immunotherapy, which should promote their valuable consideration for clinical practice.

**microRNA-Based Chemotherapy**

**Fluorouracil Resistance**

According to the National Comprehensive Cancer Network clinical practice guidelines in GC, 5-FU is recommended as the first-line anti-tumor drug. Several miRNAs have been identified to participate in the anti-tumor mechanism of 5-FU by decreasing the expression levels of various target genes. For example, overexpression of miR-939, miR-623, miR-429, miR-204, miR-124 or miR-31 was shown to enhance 5-FU-induced chemosensitivity by compromising tumor cell growth or inducing apoptosis. Among the above-mentioned miRNAs, miR-939 and miR-204 were the only two miRNAs with confirmed ability of reversing drug resistance both in vitro and in vivo, providing more convincing evidence than others. A role of miR-31 in chemosensitivity was reported by two separate research groups and may have more obvious effects. Moreover, reduced miR-6785-5p, miR-193-3p, or miR-147 expression could also increase the chemosensitivity of GC to 5-FU. Interestingly, miR-193-3p and miR-147 both target phosphatase and tensin homolog (PTEN) to exert their functions in GC. In addition to miR-193-3p and miR-147, PTEN was identified as the target gene of numerous other miRNAs and to play a role in other drug resistance and treatment mechanisms of GC, which will be discussed in further detail below. The full list of miRNAs reported to be involved in the 5-FU resistance in GC to date is provided in Table 1.

**Cisplatin Resistance**

Cisplatin (DDP) is another first-line chemotherapy drug, and the mechanism of cisplatin resistance has been the most frequently studied according to our review of the literature. As shown in Table 2, the majority of reported miRNAs (34 at the time of writing this review) can reverse DDP resistance, whereas some miRNAs (13 included in this review) could induce DDP resistance. Overexpression of miR-421, miR-320a, miR-192-5p, miR-181a, miR-148a-3p, miR-145 and miR-let-7b, and reduced expression of miR-135b-5p and miR-21-5p could enhance the chemosensitivity to DDP, which was observed in both GC cell lines and in animal tumor models. These miRNAs could become more promising targets for further clinical research after resolving some key technical problems, such as selecting suitable carrier for mimics and inhibitors of miRNAs. Moreover, although miR-218, miR-200c, miR-198, miR34a, and miR-30a were only investigated in cell lines, each of these microRNAs was reported to be involved in DDP resistance in more than one separate study, suggesting that they warrant further attention.

The miRNAs reported to be involved in the mechanism of DDP resistance mainly influence the phosphatidylinositol 3-kinase (PI3K)/AKT, mitogen-activated protein kinase (MAPK), and nuclear factor kappa B (NF-κB) signaling pathway. However, different miRNAs may have opposite effects on the same pathway. For example, miR-206 targets MAPK to enhance the chemosensitivity to DDP, and miR-135b-5p targets mammalian ste20-like kinase 1 (MST1) through the MAPK signaling pathway to induce drug resistance. Thus, it may be necessary to consider the antagonistic effects of different miRNAs in reversing drug
resistance in future studies. In addition, some genes were identified to be targets of more than one miRNA, such as survivin (miR-218, miR-34a), PTEN (miR-106a, miR-21-5p), P-glycoprotein (P-gp) (miR-129, miR-30a), and insulin-like growth factor 1 receptor (IGF1R) (miR-1271, miR-143). Thus, it will be worth considering whether there is a synergistic effect between different miRNAs in future research on DDP resistance. Furthermore, some long non-coding RNAs (HOTAIR, MALAT1, CASC2) and circular RNAs (hsa_circ0081143, circAKT3) were found to function as competing endogenous RNAs in the regulation of cisplatin resistance. These findings also provide more possibilities for microRNA-based therapies in GC treatment.

Other Single-Drug Resistance

Some studies have also indicated roles of miRNAs in the resistance of other clinically used chemotherapy drugs, including doxorubicin (DOX; also named adriamycin, ADR), paclitaxel (PTX), oxaliplatin (OXA), vinorelbine (VCR), taxol, and docetaxel (Table 3). DOX, as an anthracycline-based anti-tumor agent, is widely used for the treatment of various solid tumors such as GC. Increased expression levels of miR-494, miR-422a, miR-140, miR-103/107, and miR-16-1, and reduced levels of miR-501-5p and miR-21-5p promoted the chemosensitivity to DOX (for more details, refer to Table 3). Among these, miR-103 and miR-107 were the only miRNAs demonstrated to have effects on resistance both in vitro and in vivo. Another important miRNA that is taking the spotlight in chemotherapy resistance research is miR-21. miR-21-5p targets PTEN to induce both DOX and DDP resistance. Notably, PTEN is not only a target gene of miR-21-5p but is also a target of miR-193-3p, miR-147, and miR-106a. Through targeting PTEN, miRNAs regulate 5-FU, DDP, and DOX resistance in GC.

Table 1 miRNAs Involved in the 5-Fluorouracil (5-FU) Resistance in Gastric Cancer

| miRNA    | Target(s)* | Expression Level** | Mechanism                                  | Object***                                      | Reference |
|----------|------------|--------------------|--------------------------------------------|------------------------------------------------|
| miR-6785-5p | FOX4        | ↓                  | Apoptosis                                  | Cell lines (SGC-7901/5-Fu)                     | [20]      |
| miR-939  | SLC34A2    | ↑                  | Enhance cell growth and apoptosis via Raf/EMK/EPK pathway | Cell lines (SGC7901, MNK45 and AGS) and in vivo (SGC7901) | [9]       |
| miR-623  | CCND1      | ↑                  | Apoptosis                                  | Cell lines (SGC7901 and BGC823)                | [13]      |
| miR-429  | Bcl-2       | ↑                  | Apoptosis                                  | Cell lines (AGS)                               | [14]      |
| miR-204  | TGFB2       | ↑                  | Suppressed TGFB2-mediated EMT via TGFBβ pathway | Cell lines (AGS and SGC7901) and in vivo (AGS) | [15]      |
| miR-193-3p | PTEN        | ↓                  | Not investigated                           | Cell lines (AGS and MKN45)                    | [21]      |
| miR-147  | PTEN        | ↓                  | PI3K/AKT signaling pathway/ apoptosis      | Cell lines (AGS and BGC823)                   | [22]      |
| miR-124  | EZH2        | ↑                  | Apoptosis                                  | Cell line (AGS)                               | [16]      |
| miR-31   | ZH2         | ↑                  | G2/M cell cycle arrest                     | Cell lines (AGS)                               | [17]      |
|          | RhoA        | ↑                  | Not investigated                           | Cell line (MKN45)                             | [18]      |
|          | EZF6/SMUG1  | ↑                  | Not investigated                           | Cell line (MKN45)                             | [19]      |

Notes: *Targets genes were confirmed by Western blotting, RT-qPCR or dual-luciferase. **Upregulation (↑) or downregulation (↓) of miRNAs enhance chemosensitivity. ***The drug resistance properties of microRNAs were investigated in cell lines or in vivo.
Table 2 miRNAs Involved in the Cisplatin (DDP) Resistance in Gastric Cancer

| miRNA   | Target(s)* | Expression Level** | Mechanism | Object***                      | Reference          |
|---------|------------|--------------------|-----------|--------------------------------|--------------------|
| miR-4295 | LRIG1      | ↓                  | LRIG1-mediated EGFR/PI3K/Akt signaling pathway | Cell lines (MKN28 and MKN45) | [41]               |
| miR-1271 | IGF1R, IRS1, mROR, BCL2 | ↑                | Apoptosis | Cell lines (SGC7901/DDP)        | [52]               |
| miR-646  | CDK6       | ↑                  | hsa_circ_0081143/miR-646/CDK6 | Cell lines (SGC7901 and MGC803) | [54]               |
| miR-524-5p | SOX9      | ↑                  | Modulate proliferation and metastasis | Cell lines (SC-M1 and AZ521) | [116]              |
| miR-421  | E-cadherin, caspase-3 | ↑                | HIF-1α/miR-421/E-cadherin and caspase | Cell lines (SCG7901 and AGS) and in vivo (SGC7901) | [23]               |
| miR-375  | ERBB2      | ↑                  | ERBB2/PI3K/Akt pathway | Cell lines (SGC7901 and SGC7901/DDP) | [42]               |
| miR-320a | ADAM10     | ↑                  | Not investigated | Cell lines (SGC7901 and BGC823) and in vivo (SGC7901) | [24]               |
| miR-218  | survivin   | ↑                  | Not investigated | Cell lines (SGC7901 and SGC7901/DDP) | [32]               |
| miR-214  | PARP9, XRCC, LIN28B, CD81 | ↓                | Not investigated | Cell lines (SGC7901 and SGC7901/DDP) | [10]               |
| miR-206  | MAPK       | ↑                  | MAPK signaling pathway | Cell lines (SGC7901, SGC7901/DDP, BGC823 and BGC823/DDP) | [43]               |
| miR-200c | ZEB2       | ↑                  | Not investigated | Cell lines (SGC7901/DDP) | [34]               |
| miR-198  | PIK3R1     | ↑                  | circAKT3/miR-198/PIK3R1 | Cell lines (BGC823/CDDP, SGC7901/ CDDP) | [36]               |
| miR-203  | FGFR1      | ↑                  | Apoptosis | Cell line (SGC7901) | [37]               |
| miR-193a-3p | SRCF2    | ↓                  | Mitochondrial apoptosis pathway | Cell lines (CD44+ MKN45 and CD44- MKN45) | [117]              |
| miR-192-5p | ERCC3, ERCC4 | ↑                | NER pathway | Cell lines (SGC7901 and SGC7901/DDP) and in vivo (SGC7901/DDP) | [25]               |
| miR-181a | ATG5       | ↑                  | Autophagy | Cell lines (SGC7901/DDP) and in vivo (SGC7901/DDP) | [26]               |
| miR-149  | FoxM1      | ↑                  | Not investigated | Cell lines (SGC7901/DDP) | [118]              |
| miR-148a-3p | AKAP1, RAB12 | ↑                | Autophagy | Cell lines (BGC823/DDP and SGC7901/ DDP) and in vivo (BGC823 and BGC823/ CDDP) | [27]               |
| miR-145  | APRIL      | ↑                  | NF-kB signaling pathway | Cell lines (SGC7901 and AGS) and in vivo (AGS) | [31]               |
| miR-143  | IGF1R, BCL2 | ↑                  | Apoptosis | Cell lines (SGC7901/DDP) | [53]               |

(Continued)
Table 2 (Continued).

| miRNA     | Target(s)*          | Expression Level** | Mechanism                      | Object***                                      | Reference |
|-----------|---------------------|--------------------|--------------------------------|------------------------------------------------|-----------|
| miR-138-5p| ERCC1, ERCC4        | ↑                  | Not investigated               | Cell lines (SGC7901/DDP)                      | [119]     |
| miR-136   | AEG-1, BCL2         | ↑                  | Apoptosis                      | Cell line (AGS)                               | [120]     |
| miR-135b-5p| KLF4              | ↓                  | NF-κB signaling pathway        | Cell lines (SNU1 and MKN45)                   | [44]      |
|           | MST1                | ↓                  | MAPK signaling pathway         | Cell lines (MKN28 and MKN45) and in vivo (Not Mentioned) | [29]      |
| miR-129   | P-gp                | ↑                  | Apoptosis                      | Cell lines (BGC823/DDP and MKN45/DDP)         | [50]      |
| miR-126   | EGFA, PIK3R2        | ↑                  | HOTAIR/miR-126/VEGFA and PIK3R2→PI3K/AKT/MRP1 pathway | Cell lines (SGC7901 and SGC7901/DDP)         | [45]      |
| miR-125b  | HER2                | ↑                  | Not investigated               | Cell lines (HGC27 and MGC803)                 | [121]     |
| miR-106a  | PTEN                | ↓                  | PTEN/Akt pathway               | Cell lines (SGC7901 and SGC7901/DDP)         | [46]      |
| miR-99a and miR-491| CAPNS1                | ↓                  | Not investigated               | Cell lines (BGC823, BGC823/DDP, SGC7901 and SGC7901/DDP) | [122]     |
| miR-34a   | survivin            | ↑                  | PI3K/AKT/surviving signaling pathway | Cell lines (SGC7901 and SGC7901/DDP)         | [38]      |
|           | ABCB1, ABCCC, ABCG2 | ↑                  | HOTAIR/miR-34a→PI3K/Akt and Wnt/β-catenin signaling pathway | Cell lines (BGC823/DDP and SGC7901/DDP) | [39]      |
|           | MET                 | ↑                  | Proliferation and apoptosis    | Cell lines (SGC7901 and SGC7901/DDP)         | [40]      |
| miR-30b   | ATG5                | ↑                  | MALAT1/miR-30b/ATG5            | Cell lines (AGS/DDP and HGC27/DDP)            | [53]      |
| miR-30a   | Snail, Vimentin     | ↑                  | EMT                            | Cell lines (SGC7901 and SGC7901/DDP)         | [123]     |
|           | P-gp                | ↑                  | Autophagy                      | Cell lines (SGC7901 and SGC7901/DDP)         | [51]      |
| miR-26a   | NRAS, E2F2          | ↑                  | Not investigated               | Cell lines (SGC7901 and SGC7901/DDP)         | [124]     |
| miR-25    | FOXO3a              | ↓                  | Not investigated               | Cell lines (SGC7901 and SGC7901/DDP)         | [125]     |
| miR-22    | ENO1                | ↑                  | miR-22/ENO1↓/glycolysis↓→reverse cisplatin-resistance | Cell lines (BGC823/DDP and MGC803)         | [126]     |
| miR-21-5p | Caspase-8           | ↓                  | NF-κB/miR-21/caspase-8-P-gp    | Cell lines(BGC823, BGC823/DDP, SGC7901 and SGC7901/DDP) | [47]      |
|           | PTEN                | ↓                  | PTEN/PI3K/Akt pathway          | Cell lines (SGC7901 and SGC7901/DDP)         | [48]      |
|           | PTEN                | ↓                  | PTEN/PI3K/Akt pathway          | Cell lines (MFC and MGC803) and in vivo (MFC) | [30]      |
| miR-20a   | CYLD                | ↓                  | NF-κB signaling pathway        | Cell lines (SGC7901 and SGC7901/DDP)         | [49]      |
| miR-19a   | Not investigated    | ↓                  | CASC2(lncRNA)/miR-19a         | Cell lines (BGC823, BGC823/DDP, SGC7901 and SGC7901/DDP) | [56]      |
| miR-7     | mTOR                | ↑                  | Not investigated               | Cell line (SGC7901)                           | [127]     |

(Continued)
Among the above-mentioned miRNAs, they transplanted SGC7901/VCR cells into the right. MiR-223 could modulate apoptosis whereas miR-200c inhibits. Interestingly, miR-361-3p and miR-361-5p were reported to regulate the resistance of different drugs. This indicates that to best exploit the potential of microRNA-based tumor therapies, we need to pay attention to both the 3p- and 5p-arms of the same miRNA in addition to considering the functions of different miRNAs.

### Multidrug Resistance

Although chemotherapy resistance is a challenge for all cancer treatments, it is considered to be a particularly more complex problem in the clinical treatment of GC. In addition to single-drug resistance, multidrug resistance (MDR) may be even more common in clinical practice. Some studies have focused specifically on the roles of miRNAs in MDR (Table 4). Both in vitro and in vivo studies confirmed that miR-508-5p, miR-23b-3p, and miR-590-5p strongly regulate MDR. Shang’s group revealed that the restoration of miR-508-5p reversed the 5-FU, DDP, DOX, and VCR resistance of a xenograft in an animal model by targeting ATP binding cassette subfamily B member 1 (ABCB1) and zinc ribbon domain-containing 1 (ZNRD1). The same group further identified that the miR-27b-CCNG1-P53-miR-508-5p axis regulated the MDR of GC. They transplanted SGC7901/VCR cells into the right flanks of mice, which were then treated with an agomir for miR-27b or control oligonucleotides before 5-FU or DDP therapy, demonstrating that miR-27b overexpression reversed drug resistance. An et al. found that miR-23b-3p sensitized GC cells to 5-FU, DDP, and VCR by targeting autophagy-related gene 12 (ATG12) and high-mobility group box 2 (HMGB2). Subsequently, another study showed that the long non-coding RNA MALAT1 regulates autophagy-associated chemoresistance via the miR-23b-3p/ATG12 pathway. Shen et al. found that miR-590-5p reduces the sensitivity of GC cells to DDP and PTX. To further verify the effect of miR-590-5p, stable miR-590-5p-expressing SGC7901 cells were inoculated into nude mice and the tumor-bearing mice were treated with DDP, demonstrating that miR-590-5p reduced chemosensitivity. Compared with other reported miRNAs related to MDR (see Table 4 for the full list), there is more sufficient and reliable preclinical evidence for these three above-mentioned miRNAs, demonstrating their suitability for further research toward their potential clinical application.

Figure 1 schematically illustrates the proposed relationship between chemotherapy drugs and relevant miRNAs based on the results of studies of single-drug resistance and MDR. Figure 2 shows the relationship between miRNAs that have an effect on drug resistance and their target genes. It is now clear that some miRNAs can regulate the resistance of different drugs simultaneously. Therefore, this review should be beneficial for the design of future drug resistance studies to select the most suitable miRNAs according to different clinical application purposes. Given the pace of this field along with continuous advances in sequencing technologies, we also believe that more miRNAs that participate in the drug resistance mechanisms will be discovered with further research.

### microRNA-Based Targeted Therapy

Thus far, the majority of research focused on microRNA-based targeted therapy has focused on miRNAs that affect the resistance to targeted drugs (trastuzumab and lapatinib) and development of new types of transport carriers (synthetic nanoparticles/compounds and exosomes).

### Trastuzumab and Lapatinib

Trastuzumab as a HER2-targeting antibody has been successfully used in combination with chemotherapy for the treatment of HER2-neu overexpressing GC. Trastuzumab resistance is considered to be a difficult problem in clinical application. Increased miR-223, miR-200c, and reduced miR-21 were reported to reverse trastuzumab resistance via different mechanisms. MiR-223 could modulate apoptosis to enhance the sensitivity of a HER2-positive GC cell line to trastuzumab through targeting F-box and WD repeat domain-containing 7 (FBXW7), whereas miR-200c inhibits TGF-β-induced epithelial–mesenchymal transition to restore resistance. Among the above-mentioned miRNAs, only miR-135a, miR-1284, and miR-647 were studied both in vitro and in vivo. Interestingly, miR-361-3p and miR-361-5p were reported to regulate the resistance of different drugs. This indicates that to best exploit the potential of microRNA-based tumor therapies, we need to pay attention to both the 3p- and 5p-arms of the same miRNA in addition to considering the functions of different miRNAs.
trastuzumab sensitivity through inhibiting zinc finger E-box binding homeobox 1 (ZEB1) and ZEB2,\textsuperscript{81} and miR-21 significantly suppressed trastuzumab-induced apoptosis and decreased the sensitivity of GC cells to trastuzumab through regulating PTEN expression.\textsuperscript{82} In addition to the above three miRNAs, Sun et al\textsuperscript{83} reported a correlation between miR-125b and trastuzumab resistance according to the clinicopathologic characteristics of patients with GC. Nishida et al\textsuperscript{84} reported that the inhibitory effect of miR-125a-5p on GC proliferation was enhanced in combination with trastuzumab.

### Table 3 miRNAs Involved in Other Drug Resistance in Gastric Cancer

| miRNA  | Drug | Target(s)* | Expression Level** | Mechanism | Object*** | Ref. |
|--------|------|------------|-------------------|-----------|-----------|------|
| miR-1284 | VCR  | EIF4A1     | ↑                 | Not investigated | Cell lines (SGC7901/VCR) and in vivo (SGC7901/VCR) | \[71\] |
| miR-647  | VCR  | ANK2       | ↑                 | Apoptosis   | Cell lines (SGC7901/VCR) and in vivo (SGC7901/VCR) | \[72\] |
| miR-501-5p | DOX | BLID       | ↓                 | Akt signaling pathway | Cell lines (SGC7901 and SGC7901/ADR) | \[62,63\] |
| miR-494  | DOX  | PDE4D      | ↑                 | Not investigated | Cell line (AGS/DOX) | \[57\] |
| miR-422a | DOX  | MEF2D      | ↑                 | IncR-D63785 /miR-422a/ MEF2D | Cell line (BGC823) | \[58\] |
| miR-361-3p | OXA | ABCB1      | ↑                 | IncR-BLACAT1 /miR-361/ ABCB1 | Cell lines (BGC823/OXA and SGC7901/OXA) | \[68\] |
| miR-361-5p | Docetaxel | FOXM1 | ↑                 | PI3K/Akt/ mTOR pathway | Cell lines (SGC7901 and MKN28) | \[74\] |
| miR-200a | Taxol | β-catenin  | ↑                 | Wnt/β-catenin signaling pathway | Cell lines (SGC7901 and BGC823) | \[73\] |
| miR-155-5p | PTX | GATA3, TP53INP1 | ↓ | Not investigated | Cell lines (MGC803 and MGC803/PTX) | \[66\] |
| miR-140  | DOX  | SOX4       | ↑                 | Not investigated | Cell line (HGC27) | \[59\] |
| miR-135a | OXA  | E2F1       | ↓                 | Sp1/DAPK signaling pathway | Cell lines (SGC7901/OXA and MGC803/OXA) and in vivo(SGC7901/OXA and MGC803/OXA) | \[69\] |
| miR-103/107 | DOX | Cav-1      | ↑                 | Not investigated | Cell lines (SGC7901/ADR) and in vivo (SGC7901/ADR) | \[60\] |
| miR-34c-5p | PTX | MAPT       | ↑                 | Not investigated | Cell lines (SGC7901 and SGC7901/VCR) | \[67\] |
| miR-27a  | OXA  | P-gp, LRP, Bcl-2 | ↑ | HIF-α/miR-27a/ P-gp, LRP, Bcl-2 | Cell line (OCUM-2MD3/OXA) | \[70\] |
| miR-21-5p | DOX | PTEN,TIMP3 | ↓                 | Not investigated | Cell line (SGC7901/DOX) | \[64\] |
| miR-21   | PTX  | P-gp       | ↓                 | Not investigated | Cell line (SGC7901 and SGC7901/PTX) | \[65\] |
| miR-16-1 | DOX  | FUBP1      | ↑                 | Not investigated | Cell line (SGC7901/DOX) | \[61\] |

Notes: *Targets genes were confirmed by Western blotting, RT-qPCR or dual-luciferase. **Upregulation (↑) or downregulation (↓) of miRNAs enhance chemosensitivity. ***The drug resistance properties of microRNAs were investigated in cell lines or in vivo.

Abbreviations: VCR, vincristine; DOX (ADR), doxorubicin (adriamycin); OXA, oxaliplatin; PTX, paclitaxel.
### Table 4 miRNAs Involved in Multidrug Resistance (MDR) in Gastric Cancer

| miRNA   | Drug          | Target(s)*                  | Expression | Mechanism                           | Object***                             | Reference |
|---------|---------------|-----------------------------|------------|--------------------------------------|---------------------------------------|-----------|
| miR-874 | DDP, S-FU, VCR| ATG16 L1                    | ↑          | Apoptosis                            | Cell lines (SGC7901 and SGC7901/DDP) | [128]     |
| miR-633 | DDP, DOX,     | FADD                        | ↑          | Foxo3a/miR-633/FADD                  | Cell lines (SGC7901)                  | [129]     |
| miR-590-5p | DDP, PTX | RECK                        | ↓          | AKT/ERK and STAT3 signaling pathway  | Cell lines (SGC7901 and BGC823) and in vivo (SGC7901) | [79]     |
| miR-567 | 5-FU, OXA     | PIK3AP1                     | ↑          | miR-567-PIK3AP1-P13K/AKT-c-Myc       | Cell lines (MGC803 and BGC823)        | [130]     |
| miR-508-5p | 5-FU, DDP, VCR, DOX | ABCB1, ZNRD1                | ↑          | Not investigated                     | Cell lines (SGC7901/VCR and SGC7901/ADR) and in vivo (SGC7901/VCR) | [75]     |
| miR-495 | 5-FU, DDP, DOX, MMC | ERBB2                      | ↑          | mTOR signaling pathway               | Cell line (SGC7901)                   | [131]     |
| miR-363 | 5-FU, DDP, Docetaxel | FBW7                       | ↓          | Not investigated                     | Cell lines (MGC803 and HGC27)         | [132]     |
| miR-217 | DOX, PTX      | Not investigated            | ↑          | HOTAIR/miR-217                       | Cell line (SGC7901)                   | [133]     |
| miR-200c | DDP, Cetuximab | RhoE                        | ↑          | Not investigated                     | Cell line (SGC7901/DDP)               | [134]     |
| miR-195-5p | 5-FU, OXA | ZNF139                      | ↑          | Not investigated                     | Cell line (MKN28)                     | [135]     |
| miR-185 | 5-FU, DOX, XOA | Not investigated            | ↓          | ZNF139/miR-185                       | Cell line (SGC7901 and SGC7901/ADR)   | [136]     |
| miR-181b | 5-FU, DDP, DOX, VCR, VP-16 | BCL2                      | ↑          | Not investigated                     | Cell lines (A549/DDP and SGC7901/VCR) | [137]     |
| miR-126 | VCR, DOX      | EZH2                        | ↑          | Not investigated                     | Cell lines (SGC7901/VCR and SGC7901/ADR) | [138]     |
| miR-107 | 5-FU, DOX, PTX, OXA | Not investigated            | ↑          | Lin-28/miR-107                       | Cell lines (MKN45 and MKN48)          | [139]     |
| miR-101 | DDP, VCR      | ANXA2                       | ↑          | Not investigated                     | Cell lines (SGC7901/DDP and SGC7901/VCR) | [140]     |
| miR-96  | DDP, DOX      | FOXO1                       | ↓          | miR-96/FOXO1/p21                     | Cell lines (SGC7901)                  | [141]     |
| miR-33b-5p | DDP, Docetaxel | HMGA2                      | ↑          | Not investigated                     | Cell lines (SGC7901 and MGC803)       | [142]     |
| miR-30a | DDP, S-FU     | P-gp                        | ↑          | Decrease the MDR-related protein P-gp | Cell lines (SGC7901 and SGC7901/DDP)  | [143]     |
| miR-29c | DDP, Docetaxel | CTNND1                     | ↑          | Not investigated                     | Cell lines (MGC803 and HGC27)         | [144]     |

(Continued)
chemotherapy drugs to the target, which will be discussed further in the following section.

Lapatinib, a type of tyrosine kinase inhibitor, is also commonly used in GC targeted treatment. The resistance to lapatinib can be reversed by miR-494. Like trastuzumab, lapatinib can induce miR-16 upregulation in GC sensitive cells via inhibition of c-Myc and the PI3K/AKT and Erk1/2 pathways.

Synthetic Nanoparticles and Compounds

As mentioned above, some studies have explored the applications of nanoparticles loaded with mimics/inhibitors of miRNAs or some other tumor-targeting compounds. Song’s team constructed a tumor-targeted gene carrier, PPP, through modification of phenylboronic acid onto the surface of a polyamidoamine dendrimer. The carrier PPP showed favorable miRNAs binding and condensation ability, protected miRNAs against nuclease degradation, and mediated the cellular uptake of miRNAs. Jang’s team used nanoparticles containing poly (1-lysine-graft-imidazole) (PLI)/miRNA complexes (NVs/miR) to systemically deliver miRNA to the target site. Incorporation of hydrophilic PEG molecules on the nanoparticle surface could further prolong the blood circulation. Li’s team loaded sorafenib (SRF) and all-trans retinoic acid (ATRA) in PEGylated solid lipid nanoparticles (SLNs) composed of Gelucire, and loaded miRNA onto the surface of the SLNs based on the electrostatic interaction. Liu’s team employed intelligent gelatinases-stimuli nanoparticles to co-deliver miRNA and docetaxel to inhibit cancer stem cells. Hu’s team and Wu’s team each introduced PCL-PEG nanoparticles coated with trastuzumab (HER-PEG-PCL NPs) to control the delivery of the inhibitor of miRNA. These studies, respectively, verified the inhibitory function of miR-34a, miR-21, miR-542-3p, and miR-200c on GC in vitro or in vivo. Importantly, these strategies involve the use of synthetic nanoparticles and compounds to attempt to solve the problem of improving microRNAs-targeted transport to tumors so as to promote the clinical application of microRNA-based targeted therapies.

Exosomes

Exosomes are nanosized extracellular membrane-derived vesicles that are secreted by various cells. In 2007, miRNAs were first identified to be transferred in exosomes. In a study...
on the DDP resistance mechanism, miR-21 was identified within the exosomes secreted by tumor-associated macrophages and could be directly transferred from macrophages to GC cells to promote DDP resistance. Similarly, the exosomal transfer of miR-501-5p from DOX-resistant GC SGC7901/ADR cells to SGC7901 cells enhanced recipient cell growth, metastasis, and chemoresistance. Moreover, the exosomal delivery of miR-155-5p was suggested to induce chemoresistant phenotypes from paclitaxel-resistant GC cells to sensitive cells. Given the potential of genetic exchange between cells via exosomes, they have been considered as an alternative promising tool for therapeutic purposes, including in microRNA-based treatment. To support this possibility, one study transfected inhibitors of miR-214 and a negative control into HEK293T cells, and exosomes extracted from the cell medium after 48 h were verified to contain the inhibitor of miR-214, which reversed the resistance to DDP both in GC cells and in vivo. In applications for reversing drug resistance or directly suppressing tumors, exosomes containing mimics or inhibitors of miRNAs are likely safer than synthetic nanoparticles and compounds. However, more research is needed to solve exosome-related technical problems, such as the lack of methods to interfere with the packaging of cargo or with vesicle release, before microRNA-based targeted therapies can become a reality.

**microRNA-Based Tumor Immunotherapy**

In the past decade, tumor immunotherapy has made great progress in both scientific research and clinical application. Novel drugs target immune checkpoint molecules, such as programmed cell death protein 1 (PD-1), PD-1
ligand cytotoxic, and T lymphocyte antigen-4 (CTLA-4), and augment T-cell activity. The use of immune checkpoint inhibitors has been approved in several tumors, and they are showing remarkable clinical effects. However, only a limited number of GC patients respond to tumor immunotherapy. Few studies have focused on the functions of miRNAs in immunotherapy for GC. Fan et al\textsuperscript{93} reported that Cbl proto-oncogene B (Cbl-b) as a target gene of miR-940 interacted and ubiquitinated signal transducer and activator of transcription 5a (STAT5a) and down-regulated the expression of STAT5a and anti-programmed death ligand-1 (PD-L1). The miR-940/Cbl-b/STAT5a/PD-L1 axis promoted the proliferation and migration of gastric cancer cells. Accordingly, similar researches can perhaps provide some new ideas and conjectures for microRNA-based immunotherapies of GC.

**Figure 2** Schematic diagram showing the relationship between target genes and miRNAs related to drug resistance.

**microRNA-Based Other Therapies**

The upstream regulatory mechanism of miRNAs, such as hypermethylation in the promoter region and transcription factor dysregulation, affects the expression of miRNAs. Some miRNAs play key roles in GC tumorigenesis, proliferation, metastasis, and recurrence. In theory, many genes and miRNAs in these processes could become potential therapeutic targets. However, there are too many possible miRNAs and related mechanisms involved in GC to give a detailed
| miRNA     | Drug            | Mechanism                          | Object*                  | Reference |
|-----------|-----------------|------------------------------------|--------------------------|-----------|
| miR-4670-5p | Aspirin         | Aspirin→miR-4670-5p↓→suppress proliferation | Cell lines (MKN45, NUGC3 and AGS) and in vivo (MKN45) | [99]      |
| miR-940   | PD-L1           | miR-940↑→Cbl-b↓→ubiquitination regulation of STAT5a→PD-L1↑→promote proliferation and migration of GC | Cell lines (MGC803, AGS, NCI-N87 and MKN74) and in vivo (MGC803) | [93]      |
| miR-494   | Cibinocucinic    | Cibinocucinic→miR-494↑→BAG-1↓→inhibit cell proliferation and promote apoptosis | Cell lines (BGC823 and SGC7901) | [97,98]   |
|           | TNF-related apoptosis-inducing ligand (TRAIL) | miR-494↑→survivin↓→sensitize GC cells to TRAIL-induced cytotoxicity | Cell lines (BGC823 and MGC803) | [103]     |
| miR-493   | Dickkopf-1 (DKK1) | miR-493↑→DKK1↓→promote proliferation, invasion and chemo-resistance | Cell lines (SGC7901, MKN28, AGS and MGC803) and in vivo (MGC803 and SGC7901) | [100]     |
| miR-388-5p| Anticancer bioactive peptide-3 (ACBP-3) | ACBP-3→miR-388-5p↑, BAK↑, BIM↑→inhibit gastric cancer stem cell (GCSC) proliferation and induce apoptosis and lower the required effective dose of DDP or 5-FU | Cell lines (MKN45, MKN74 and GES-1) | [150]     |
| miR-298   | Bufalin          | Bufalin→miR-298↓→BAX↑→inhibit gastric cancer stem cell (GCSC) proliferation and induce apoptosis | Cell lines (MKN45, MGC803, SGC7901 and GES-1) | [151]     |
| miR-203   | Berberine (BER)  | BER→miR-203↑→Bcl-w↓→reduce DDP resistance | Cell lines (SGC7901, BGC823, SGC7901/DDP and BGC823/DDP) | [152]     |
| miR-195   | Propofol         | Propofol→miR-195↑→inactivate JAK/STAT and NF-κB pathway→suppress proliferation, migration, invasion and promote apoptosis | Cell lines (MKN45) | [153]     |
| miR-181a  | Kaempferol       | Kaempferol→miR-181a↑→inactivate MAPK/ERK and PI3K pathway→suppress proliferation and promote autophagy, but not apoptosis | Cell lines (SNU216 and GES-1) | [154]     |
| miR-133a  | Ursolic acid (UA)| UA→miR-133a↑→Bax/caspase 3/Bcl2↓→inhibit GC growth and metastasis | Cell lines (BGC823) | [155]     |
| miR-124   | Sulforaphane (SFN)| SFN→miR-124↑→IL-6R↓, STAT3↓→enhance the anti-cancer function of DDP | Cell lines (MGC803 and BGC823) | [104]     |
|           | Paeonolfinor    | Paeonolfinor→miR-124↑→inhibit PI3K/Akt and STAT3 signaling→inhibit cell viability and induce apoptosis | Cell lines (MGC803 and GES-1) | [105]     |
| miR-106b  | Docosahexaenoic acid (DHA) | DHA+docetaxel→MMP2↓ and DHA lower the docetaxel-mediated upregulation of miR-106b | Cell lines (MKN45) | [156]     |
| miR-34a   | Luteolin         | Luteolin→miR-34a↑→HK1↓→p53/p21 and MAPK/ERK pathway→inhibit GC and induce G1 phase arrest→modulate the susceptibility of GC to luteolin | Cell lines (AGS, BGC823 and SGC7901) | [106]     |
|           |                 | Luteolin→miR-34a↑→Bcl-2↓→inhibit proliferation and induce apoptosis | Cell lines (BGC823 and SGC7901) | [107]     |
|           | Diallyl disulfide (DADS) | DADS→miR-34a↑→inhibit PI3K/Akt signaling pathway→inhibit invasion and induce apoptosis | Cell lines (SGC7901) | [108]     |
| Chrysin   | Chrysin loaded PLGA-PEG-PLGA rather than free chrysin→miR-34a↑ | Cell lines (AGS) | [109]     |

(Continued)
description of them in just one paper. Some miRNAs, regarded as potential therapeutic targets, have also had been reviewed elsewhere. Our review focused more on discussing miRNAs that are more promising for clinical use. We believe that miRNAs that have an effect on GC treatment (including chemotherapy, targeted therapy, immunotherapy, and others) could also become core targets in microRNA-based therapies. It is reported that some drugs with anti-tumor effects may play roles by altering the expression of miRNAs and their related pathways. For example, cinobufacini, which is widely used in the treatment of advanced cancers, was reported to suppress cell proliferation and induce apoptosis in GC by regulating the miR-494-BAG-1 (BCL2 associated athanogene 1) axis.

Table 5 summarizes the 24 microRNAs reported to be involved in the mechanism of other anti-tumor drugs in GC treatment. Some miRNAs, such as miR-4670-5p, miR-940, miR-493, miR-30e, and miR-7, have been shown to have anti-tumor effects both in vitro and in vivo, and other miRNAs, such as miR-494, miR-124, miR-34a, miR-21, and miR-9, have been investigated in more than one study.

**Table 5 (Continued).**

| miRNA | Drug | Mechanism | Object* | Reference |
|-------|------|-----------|---------|-----------|
| miR-30e | 3,3′-Diindolylmethane (DIM) | DIM→miR-30e|→ATGS↓→block autophagy and inhibit proliferation | Cell lines (BGC823 and SGC7901) and in vivo (BGC823) | [101] |
| miR-21 | Cyclooxygenase-2 inhibitor NS398 | NS398→miR-21|→Bez21↓, Bax↑, Bak↑, PTEN↓|→induce apoptosis and decrease invasiveness | Cell lines (AGS) | [110] |
| Celastrol | Celastrol→miR-21|→inactivate PTEN/P3K/AKT and nuclear factor-{kappa}B signaling pathway|→inhibit proliferation, migration, invasion and induce apoptosis, G2/M cell cycle arrest. | Cell lines (MKN45) | [111] |
| Aspirin and lapatinib | Aspirin and lapatinib→VEGF|→miR-21↓|→attenuate P3K/AKT signaling|→inhibit proliferation and migration | Cell lines (MKN1, MKN45, MKN74 and IPM95) | [112] |
| miR-18a, miR-21, miR-221 | Chrysin loaded PLGA-PEG nanoparticles more effective than free chrysin | miR-18a↓, miR-21↓, miR-221↓ | Cell lines (AGS) | [157,158] |
| miR-17-5p | Shengfuzheng (SQFZ) | SQFZ→amplify the effects of si-HOTAIR, miR-17-5p inhibitor and overexpression of PTEN on boosting the chemosensitivity of GC | Cell lines (MGC803, SGC7901, BGC83, MKN28 and GES-1) | [159] |
| miR-16-5p | Melatonin | Melatonin→miR-16-5p↓→Smad3↑|→inhibit the growth and induce apoptosis of GC | Cell lines (BSG823 and SGC7901) | [160] |
| miR-9 and miR-326 | Sulforaphane extracted from broccoli sprout (SEBS) | SEBS→aberrant expression of miR-9, miR-326, CDX1, CDX2→anti-proliferative effects | Cell lines (AGS) | [113] |
| miR-9 and Let-7 | Chrysin-PLGA-PEG nanoparticles are more effective than pure chrysin | miR-9↑, Let-7a↑ | Cell lines (AGS) | [114] |
| miR-7 | Canolol | Canolol→miR-7|→block up of COX-2/PGE signaling pathway|→inhibit the gastritis-related tumor initiation and progression | Cell lines (AGS) and in vivo (K19-C2mE transgenic mice model which could develop hyperplastic tumors spontaneously in the glandular stomach) | [102] |

Notes: *The drug resistance properties of microRNAs were investigated in cell lines or in vivo.

**Future Prospects and Challenges**

Since Ma et al. first reported that miRNAs affected the biological behavior of tumors in 2007, more and more functions of miRNAs have been described and more and more miRNAs have been identified in different tumors, including GC. With the continual development of research on miRNAs, scientists are no longer satisfied with...
exploration of mechanisms but are now actively trying to realize the goal of clinical application and translation of achievements from the laboratory to clinical practice. Hence, microRNAs-based therapy is expected to become a promising research direction and ultimately benefit patients with GC.

The goal of the present review was not only to summarize the relevant literature and advances on the roles of miRNAs in GC treatment, but to further attempt at answering several existing questions. First, we wondered which aspects of GC treatment will microRNA-based therapies be best suited for. As reviewed herein, miRNAs can function in reversing drug resistance, directly inhibiting tumors, or enhancing the anti-tumor effects of drugs. Here, we have mainly focused on the potential for curbing drug resistance and the enhancing the anti-tumor effects of drugs. In terms of directly inhibiting tumors, we have highlighted only some key representative studies, as this field is extremely rich and therefore a comprehensive review is outside of the overall scope. Second, we have tried to assess which miRNAs are most suitable for therapeutic applications. We believe that the miRNAs verified in animal experiments and in more than one study are more reliable for further investigation. Of course, we also acknowledge that this perspective is limited by the extent and scope of current research. Therefore, further verification and screening are needed in future studies. Third, we want to determine the best method to realize the utilization of these miRNAs. Synthesized oligonucleotides of miRNA mimics or inhibitors have been used in an animal tumor model for several years with good results. However, before clinical application, more safety, targeting, and stability issues of this approach need to be considered. Recently, the application of synthetic nanoparticles/compounds and exosomes provides more promising possibilities; however, these techniques also require the combined efforts of doctors, pharmacists, and scientists of other disciplines.

Overall, we believe that this field is currently at an explosive stage of discovery, and hope that this review will promote further applications of this research to realize the ultimate goal of improving the quality of life and outcome of patients with GC.

Acknowledgment

We are grateful to Dr Pu-Jun Gao who is the doctoral supervisor of Xu Zhao for his guidance in revising this manuscript.

Author Contributions

All authors contributed to data analysis, drafting or revising the article, gave final approval of the version to be published, and agree to be accountable for all aspects of the work.

Funding

This work was supported by the National Natural Science Foundation of China (81672106).

Disclosure

All authors declare they have no conflicts of interest.

References

1. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. doi:10.3322/caac.v68.6
2. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115–132. doi:10.3322/caac.213338
3. Van CE, Sagaert X, Topal B, et al. Gastric cancer. Lancet. 2016;388(6):2654–2664. doi:10.1016/S0140-6736(16)30354-3
4. Orditura M, Galizia G, Sforza V, et al. Treatment of gastric cancer. World J Gastroenterol. 2014;20(7):1635–1649. doi:10.3748/wjg.v20.i7.1635
5. Murahashi S, Takahari D, Wakatsuki T, et al. A retrospective analysis of ranitidine monotherapy in previously treated Japanese patients with advanced or metastatic gastric adenocarcinoma. Int J Clin Oncol. 2018;23(1):92–97. doi:10.1007/s10147-017-1192-0
6. Bang YJ, Van CE, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a Phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–697. doi:10.1016/S0140-6736(10)61211-X
7. Chen Z, Li Z, Soutto M, et al. Integrated analysis of mouse and human gastric neoplasms identifies conserved microRNA networks in gastric carcinogenesis. Gastroenterology. 2019;156(4):1127–1139. doi:10.1053.j.gastro.2018.11.052
8. Miroshnichenko S, Patutina O. Enhanced inhibition of tumorigenesis using combinations of miRNA-targeted therapeutics. Front Pharmacol. 2019;10:488. doi:10.3389/fphar.2019.00488
9. Zhang JX, Xu Y, Gao Y, et al. Decreased expression of miR-939 contributes to chemoresistance and metastasis of gastric cancer via dysregulation of SLC34A2 and Raf/MEK/ERK pathway. Mol Cancer. 2017;16(1):18.
10. Wang X, Zhang H, Bai M, et al. Exosomes serve as nanoparticles to deliver anti-miR-214 to reverse chemoresistance to cisplatin in gastric cancer. Mol Ther. 2018;26(3):774–783. doi:10.1016/j.ymthe.2018.01.001
11. Song Z, Liang X, Wang Y, et al. Phenylboronic acid-functionalized polyamidoamine-mediated miR-34a delivery for the treatment of gastric cancer. Biomater Sci. 2019;7(4):1632–1642. doi:10.1039/C8BM01385C
12. Hu N, Yin JF, Ji Z, et al. Strengthening gastric cancer therapy by trastuzumab-conjugated nanoparticles with simultaneous encapsulation of anti-miR-21 and 5-fluorouridine. Cell Physiol Biochem. 2017;44(6):2158–2173. doi:10.1159/000485955
20. Yu C, Chen DQ, Liu HX, et al. Rosmarinic acid reduces the resistance of gastric cancer cells to 5-fluorouracil by down-regulating the expression of zeste homolog 2 (ZHH2). Arch Biochem Biophys. 2018;663:269–275. doi:10.1016/j.abb.2019.01.023

21. Korourian A, Roudi R, Sharifabrizi A, et al. MicroRNA-31 inhibits RhoA-mediated tumor invasion and chemotherapy resistance in MKN-45 gastric adenocarcinoma cells. Exp Biol Med (Maywood). 2017;242(18):1842–1847. doi:10.1177/1537370217728460

22. Xu C, Chen DQ, Liu HX, et al. Rosmarinic acid reduces the resistance of gastric cancer cells to 5-fluorouracil by down-regulating FOXO4-targeting miR-6785-5p. Biomed Pharmacother. 2019;109:2327–2334. doi:10.1016/j.biopha.2018.10.061

23. Jian B, Li Z, Xiao D, et al. Downregulation of microRNA-193-3p inhibits tumor proliferation migration and chemoresistance in human gastric cancer by regulating PTEN gene. Tumour Biol. 2016;37(7):8941–8949. doi:10.1007/s13277-017-3477-x

24. Shen J, Niu W, Zhang H, et al. Downregulation of microRNA-147 inhibits cell proliferation and increases the chemosensitivity of gastric cancer cells to 5-fluorouracil by directly targeting PTEN. Oncol Res. 2018;26(6):901–911. doi:10.3727/096504017X15061902533715

25. Ge X, Liu X, Lin F, et al. MicroRNA-421 regulated by HIF-1alpha promotes metastasis, inhibits apoptosis, and induces cisplatin resistance by targeting E-cadherin and caspase-3 in gastric cancer. Oncotarget. 2016;7(17):24466–24482. doi:10.18632/oncotarget.8228

26. Ge X, Cui H, Zhou Y, et al. MiR-320a modulates cell growth and chemosensitivity via targeting MET in gastric cancer. Mol Med Rep. 2017;16(6):9664–9670. doi:10.3892/mmr.2017.7819

27. Xie X, Huang N, Zhang Y, et al. MiR-192-5p reverses cisplatin resistance by targeting ERCC3 and ERCC4 in SGC7901/DDP cells. J Cancer. 2019;10(4):1039–1051. doi:10.7150/jca.25814

28. Zhao J, Nie Y, Wang H, et al. MiR-181a suppresses autophagy and sensitizes gastric cancer cells to cisplatin. Gene. 2016;576(2 Pt 2):828–833. doi:10.1016/j.gene.2015.11.013

29. Li B, Wang W, Li Z, et al. MicroRNA-148a-3p enhances cisplatin cytotoxicity in gastric cancer through mitochondrial fission induction and cyto-protective autophagy suppression. Cancer Lett. 2017;410:212–227. doi:10.1016/j.canlet.2017.09.035

30. Han X, Zhang JJ, Han QZ, et al. Let-7b attenuates cisplatin resistance and tumor growth in gastric cancer by targeting AURKB. Cancer Gene Ther. 2018;25(11–12):300–308. doi:10.1038/s41417-018-0048-8

31. Zhou J, Chen Q. Poor expression of microRNA-135b results in the inhibition of cisplatin resistance and proliferation and induces the apoptosis of gastric cancer cells through MST1-mediated MAPK signaling pathway. FASEB J. 2019;33(3):3420–3436. doi:10.1096/fj.201800618RRR

32. Zheng P, Chen L, Yuan X, et al. Exosomal transfer of tumor-associated macrophage-derived miR-21 confers cisplatin resistance in gastric cancer cells. J Exp Clin Cancer Res. 2017;36(1):53. doi:10.1186/s13046-017-0525-y

33. Zhi X, Tao J, Xiang G, et al. APRIL induces cisplatin resistance in gastric cancer cells via activation of the NF-kB pathway. Cell Physiol Biochem. 2015;35(2):571–585. doi:10.1159/000369720
47. Xin L, Yang WF, Zhan HT, et al. The mechanism study of lentiviral vector carrying methioninase enhances the sensitivity of drug-resistant gastric cancer cells to Cisplatin. Br J Cancer. 2018;118(9):1189–1199. doi:10.1038/s41416-018-0043-8
48. Yang SM, Huang C, Li XF, et al. MiR-21 confers cisplatin resistance in gastric cancer cells by regulating PTEN. Toxicology. 2013;306:162–168. doi:10.1016/j.tox.2013.02.014
49. Zhu M, Zhou X, Du Y, et al. MiR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLD. Mol Med Rep. 2016;14(2):1742–1750. doi:10.3892/mmr.2016.5413
50. Lu C, Shan Z, Li C, et al. MiR-129 regulates cisplatin-resistance in human gastric cancer cells by targeting P-gp. Biomed Pharmacother. 2017;86:450–456. doi:10.1016/j.biopha.2016.11.139
51. Du X, Liu B, Luan X, et al. MiR-30 decreases multidrug resistance in human gastric cancer cells by modulating cell autophagy. Exp Ther Med. 2018;15(5):599–605. doi:10.3892/etm.2017.5354
52. Yang M, Shan X, Zhou X, et al. MiR-1271 regulates cisplatin resistance of human gastric cancer cell lines by targeting IGFR1, IRS1, mTOR, and BCL2. Anticancer Agents Med Chem. 2014;14(6):884–891. doi:10.2174/1871520614666140528161318
53. Zhan J, Shi Q, Zhang X, et al. Involvement of miR-143 in cisplatin resistance of gastric cancer cells via targeting IGFR1 and BCL2. Tumour Biol. 2015;36(4):2737–2745. doi:10.1007/s13277-014-2989-5
54. Xue M, Li G, Fang X, et al. hsa_circ_0081143 promotes cisplatin resistance in gastric cancer by targeting miR-422a. Cancer Cell Mol Biol (Noisy-Le-Grand). 2015;20(1):275–282. doi:10.4103/1220-314-0450-2
55. Wang M, Qiu R, Yu S, et al. Paclitaxel-resistant gastric cancer MGC-803 cells promote epithelial-to-mesenchymal transition and chemoresistance in paclitaxel-sensitive cells via exosomal delivery of miR-155-5p. Int J Oncol. 2019;54(1):326–338. doi:10.3892/ijo.2018.4601
56. Wu H, Huang M, Lu M, et al. Regulation of microtubule-associated protein tau (MAPT) by miR-34c-5p determines the chemosensitivity of gastric cancer to paclitaxel. Cancer Chemother Pharmacol. 2013;71(5):1159–1171. doi:10.1007/s00280-013-2108-y
57. Xu Y, Zheng Y, Han B, et al. Long noncoding RNA BLATC1 modulates ABCB1 to promote oxaliplatin resistance of gastric cancer via sponging miR-361. Biomed Pharmacother. 2018;99:832–838. doi:10.1016/j.biopha.2018.01.130
58. Yan LH, Chen ZN, Li L, et al. MiR-135a promotes gastric cancer progression and resistance to oxaliplatin. Oncotarget. 2016;7(43):70699–70714. doi:10.18632/oncotarget.12208
59. Zhao Q, Li Y, Tan BB, et al. HIF-1α induces multidrug resistance in gastric cancer cells by inducing miR-27a. PLoS One. 2015;10(8):e0132746. doi:10.1371/journal.pone.0132746
60. Cao W, Wei W, Zhan Z, et al. MiR-1284 modulates multidrug resistance of gastric cancer cells by targeting EIF4A1. Oncol Rep. 2016;35(5):2583–2591. doi:10.3892/or.2016.4643
61. Cao W, Wei W, Zhan Z, et al. Regulation of drug resistance and metastasis of gastric cancer cells via the microRNA647-ANK2 axis. Int J Mol Med. 2018;41(4):1958–1966. doi:10.3892/ijmm.2018.3381
62. Liu X, Du P, Han L, et al. Effects of miR-200a and FH535 combined with taxol on proliferation and invasion of gastric cancer. Pathol Res Pract. 2018;214(3):442–449. doi:10.1016/j.prp.2017.12.004
63. Tian L, Zhao Z, Xie L, et al. MiR-361-5p suppresses chemoresistance of gastric cancer cells by targeting FOXM1 via the PI3K/Akt/mTOR pathway. Oncotarget. 2018;9(4):4886–4896. doi:10.18632/oncotarget.23513
64. Wang Y, Zhang Z, Liu Z, et al. MiR-508-5p regulates multidrug resistance of gastric cancer by targeting ABCB1 and ZNRD1. Oncogene. 2014;33(25):3267–3276. doi:10.1038/onc.2013.297
65. Yang Y, Feng B, Zhou L, et al. The miR27b-CCNG1-P53-miR-508-5p axis regulates multidrug resistance of gastric cancer. Oncotarget. 2016;7(1):538–549. doi:10.18632/oncotarget.7117
66. An Y, Zhang Z, Shang Y, et al. MiR-23b-3p regulates the chemoresistance of gastric cancer cells by targeting ATG12 and HMGB2. Cell Death Dis. 2015;6(1):538. doi:10.1038/cddis.2015.123
67. YiRen H, YingCong Y, Sunwu Y, et al. Long noncoding RNA MALAT1 regulates autophagy associated chemoresistance via miR-23b-3p sequestration in gastric cancer. Mol Cancer. 2016;15(7):891. doi:10.2174/1866689614666140528161318
68. Eto K, Iwatsuki M, Watanabe M, et al. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer to 5-fluorouracil. Cancer Lett. 2013;338. doi:10.1016/j.canlet.2013.05.035
69. Liu J, Xu Y. MicroRNA-140 inhibits cell proliferation in gastric cancer cell line HGC-27 by suppressing SOX4. Med Sci Monit. 2016;22:2243–2252. doi:10.12659/MSM.896633
70. Zhang Y, Qu X, Li C, et al. MiR-103/107 modulates multidrug resistance in human gastric carcinoma by downregulating Cav-1. Tumour Biol. 2015;36(4):2277–2285. doi:10.1007/s13277-014-2853-7
71. Zhao D, Zhang Y and Song L. MiR-16-1-5p targeted silences far upstream element binding protein 1 to advance the chemosensitivity to adriamycin in gastric cancer. Pathol Oncol Res. 2018;24(3):483–488. doi:10.1007/s12253-017-0263-x
72. Liu X, Lu Y, Xu Y, et al. Exosomal transfer of miR-501 confers doxorubicin resistance and tumorigenesis via targeting of BLID in gastric cancer. Cancer Lett. 2019;459:122–134. doi:10.1016/j.canlet.2019.05.035
73. Xu YC, Liu X, Li M, et al. A novel mechanism of doxorubicin resistance and tumorigenesis mediated by MicroRNA-501-5p-Suppressed BLID. Mol Ther Nucleic Acids. 2018;12:578–590. doi:10.1016/j.mtna.2018.06.011
74. Chen J, Zhou C, Li J, et al. MiR-21-5p confers doxorubicin resistance in gastric cancer cells by targeting PTEN and TIMP3. Int J Mol Med. 2016;41(4):1855–1866. doi:10.3892/ijmm.2018.3405
75. Jin B, Liu Y, Wang H. Antagonism of miRNA-21 sensitizes human gastric cancer cells to paclitaxel. Cell Biochem Biophys. 2015;72(1):275–282. doi:10.1007/s12013-014-0450-2
Polakovicova I, Jerez S, Wichmann IA, et al. Role of microRNAs in the exchange between cells. *Front Microbiol* 2015;6(3):654–659. doi:10.3389/fmicb.2015.00636

Bartakova EV, Kim MS. Using exosomes, naturally-equipped nanocarriers, for drug delivery. *J Control Release* 2015;219:396–405. doi:10.1016/j.jconrel.2015.07.030

Fan Y, Che X, Hou K, et al. MiR-940 promotes the proliferation and migration of gastric cancer cells through up-regulation of programmed death ligand-1 expression. *Exp Cell Res* 2018;373(1–2):180–187. doi:10.1016/j.yexcr.2018.10.011

Polakovcovova I, Jerez S, Wichmann IA, et al. Role of microRNAs and exosomes in helicobacter pylori and epithelium-bar virus associated gastric cancers. *Front Microbiol* 2018;9:636. doi:10.3389/fmicb.2018.00636

Matsuzaki J, Suzuki H. Role of MicroRNAs-221/222 in digestive systems. *J Clin Med* 2015;4(8):1566–1577. doi:10.3390/jcm4081566

Xie M, Dart DA, Owen S, et al. Insights into roles of the miR-1, –133 and –206 family in gastric cancer (Review). * Oncol Rep* 2016;36(3):1191–1198. doi:10.3829/ore.2016.4908

Shen Z, Li Y, Zhao C, et al. MiR-494-BAG-1 axis is involved in cibosubactin-induced cell proliferation and apoptosis in gastric cancer. * Mol Med Rep* 2018;17(5):7435–7441. doi:10.3829/mmrv.2018.8788

Zhou RP, Chen G, Shen ZL, et al. Cibosubactin suppress cell proliferation via miR-494 in BGC-823 gastric cancer cells. *Asian Pac J Cancer Prev* 2014;15(3):1241–1245. doi:10.7314/APJCPR.2014.15.3.1241

Ikimi K, Kurokawa Y, Takahashi T, et al. Antitumor effect of anti-platelet agents in gastric cancer patients: an in vivo and in vitro study. *Gastric Cancer* 2016;19(3):817–826. doi:10.1007/s10120-015-0556-2

Jia X, Li N, Peng C, et al. MiR-493 mediated DKK1 down-regulation confers proliferation, invasion and chemo-resistance in gastric cancer cells. *Oncotarget* 2016;7(6):7044–7054. doi:10.18632/oncotarget.716

Ye Y, Fang Y, Xu W, et al. 3,3'-Diindolylmethane induces anti-human gastric cancer cells by the miR-30c-ATG5 modulating autophagy. *Biochem Pharmacol* 2016;115:77–84. doi:10.1016/j.bcp.2016.06.018

Cao D, Jiang J, Tsukamoto T, et al. Canold inhibits gastric tumors initiation and progression through COX-2-PGE2 pathway in K19-C2mE transgenic mice. *PLoS One* 2015;10(3):e0120938. doi:10.1371/journal.pone.0120938

Xu S, Li D, Li T, et al. MiR-494 sensitizes gastric cancer cells to TRAIL treatment through downregulation of survivin. *Cell Physiol Biochem* 2018;51(5):2212–2223. doi:10.1159/000495867

Wang X, Li Y, Dai Y, et al. Sulforaphane improves chemotherapy efficacy by targeting cancer stem cell-like properties via the miR-124-3p and STAT3 axis. *Sci Rep* 2016;6:36796. doi:10.1038/srep36796

Zheng YB, Xiao GC, Tong SL, et al. Paeoniflorin inhibits human gastric carcinoma cell proliferation through up-regulation of microRNA-124 and suppression of PI3K/Akt and STAT3 signaling. *World J Gastroenterol.* 2015;21(23):7197–7207. doi:10.3734/wjg.v21.i23.7197

Zhao Y, Ding BZ, Lin YP, et al. MiR-34a, as a suppressor, enhance the susceptibility of gastric cancer cell to luteolin by directly targeting HK1. *Gene* 2018;644:56–65. doi:10.1016/j.gene.2017.10.046

Wu H, Huang M, Liu Y, et al. Luteolin Induces apoptosis by up-regulating miR-34a in human gastric cancer cells. *Technol Cancer Res Treat* 2015;14(6):747–755. doi:10.7785/tcrt.2012.500434

Wang G, Liu G, Ye Y, et al. Upregulation of miR-34a by diallyl disulfide suppresses invasion and induces apoptosis in SGC-7901 cells through inhibition of the PI3K/Akt signaling pathway. *Onco Lett.* 2016;11(4):2661–2667. doi:10.3892/ol.2016.4266

Mohammadian F, Abbahi A, Daruishnejad H, et al. Upregulation of microRNA-34A in AGS gastric cancer cells by a PLGA-PEG-PLGA chrysin nano formulation. *Asian Pac J Cancer Prev* 2015;16(18):8259–8263. doi:10.7314/APJCP.2015.16.18.8259

Li H, Cheng J, Mao Y, et al. MiR-21 inhibits the effects of cyclooxygenase-2 inhibitor NS398 on apoptosis and invasion in gastric cancer cells. *Onco Targets Ther.* 2015;8:3245–3253. doi:10.2147/OTT.S90012

Yao SS, Han L, Tian ZB, et al. Celastrol inhibits growth and metastasis of human gastric cancer cell MKN45 by down-regulating microRNA-21. *Phytother Res.* 2019;33(6):1706–1716. doi:10.1002/ptr.6359

Zhang W, Tan Y, Ma H. Combined aspirin and aripiprazole treatment suppresses gastric cancer cell proliferation. *Oncol Lett.* 2017;14(5):5409–5417. doi:10.3892/ol.2017.6858

Kiani S, Akhavan-Niaki H, Fattahi S, et al. Purified sulforaphane from broccoli (Brassica oleracea var. italica) leads to alterations of CDX1 and CDX2 expression and changes in miR-9 and miR-326 levels in human gastric cancer cells. *Gene* 2018;678:115–123. doi:10.1016/j.gene.2018.08.026

Mohammadian F, Pilehvar SY, Zarghami F, et al. Upregulation of miR-9 and Let-7a by nanoencapsulated chrysin in gastric cancer cells. *Artif Cells Nanomed Biotechnol.* 2017;45(4):1–6. doi:10.1080/21691401.2017.1391824

Ma L, Tenuya FJ and Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. *Nature* 2007;449(7163):682–688. doi:10.1038/nature06174

Wang J, Xue X, Hong H, et al. Upregulation of microRNA-524-5p enhances the cisplatin sensitivity of gastric cancer cells by modulating proliferation and metastasis via targeting SOX9. *Oncotarget* 2017;8(1):574–582. doi:10.18632/oncotarget.13479

Lee SD, Yu D, Lee DY, et al. Upregulated microRNA-193a-3p is an independent prognostic factor in gastric cancer and inhibits the efficiency of anti-miR-21 to HER2 positive gastric cancer. *Oncol Rep* 2015;34(4):1198–1204. doi:10.3892/or.2015.6696

Xu X, Li G, Liu Y, et al. MiR-149 reverses cisplatin resistance of gastric cancer cells through inhibition of the PI3K/Akt signaling pathway. *Mol Cancer* 2016;15(3):6253. doi:10.1186/s12943-016-0572-1

Ma L, Tenuya FJ and Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. *Nature* 2007;449(7163):682–688. doi:10.1038/nature06174

Wang J, Xue X, Hong H, et al. Upregulation of microRNA-524-5p enhances the cisplatin sensitivity of gastric cancer cells by modulating proliferation and metastasis via targeting SOX9. *Oncotarget* 2017;8(1):574–582. doi:10.18632/oncotarget.13479

Lee SD, Yu D, Lee DY, et al. Upregulated microRNA-193a-3p is an independent prognostic factor in gastric cancer and inhibits the efficiency of anti-miR-21 to HER2 positive gastric cancer. *Oncol Rep* 2015;34(4):1198–1204. doi:10.3892/or.2015.6696

Ning J, Jiao Y, Xie X, et al. MiR-138-5p modulates the expression of excision repair cross-complementing proteins ERCC1 and ERCC4, and regulates the sensitivity of gastric cancer cells to cisplatin. *Oncol Rep* 2019;41(2):1131–1139. doi:10.3892/or.2018.9097

OncoTargets and Therapy 2019:12

submit your manuscript | www.dovepress.com

Dovepress

11409
120. Yu L, Zhou GQ, Li DC. MiR-136 triggers apoptosis in human gastric cancer cells by targeting AEG-1 and BCL2. *Eur Rev Med Pharmacol Sci*. 2018;22(21):7251–7256. doi:10.26355/eurrev_201811_16259

121. Zhang X, Yao J, Guo K, et al. The functional mechanism of miR-125b in gastric cancer and its effect on the chemosensitivity of cisplatin. *Oncotarget*. 2018;9(2):2105–2119. doi:10.18632/oncotarget.23249

122. Zhang Y, Xu W, Ni P, et al. MiR-99a and miR-491 regulate cisplatin resistance in human gastric cancer cells by targeting CAPNS1. *Int J Biol Sci*. 2016;12(12):1437–1447. doi:10.7150/ijbs.16529

123. Wang LL, Zhang P, Zhang X, et al. MiR-30a increases cisplatin sensitivity of gastric cancer cells through suppressing epithelial-to-mesenchymal transition (EMT). *Eur Rev Med Pharmacol Sci*. 2016;20(9):1733–1739.

124. Wen L, Cheng F, Zhou Y, et al. MiR-26a enhances the sensitivity of gastric cancer cells to cisplatin by targeting NRAS and E2F2. *Saudi J Gastroenterol*. 2015;21(5):313–319. doi:10.1159/000432160

125. He J, Qi Y, Chen F, et al. MicroRNA-25 contributes to cisplatin resistance in gastric cancer cells by inhibiting forkhead box O3a. *Oncol Lett*. 2017;14(5):6997–6102. doi:10.3892/ol.2017.7698

126. Qian X, Xu W, Xu J, et al. Enolase 1 stimulates glycolysis to promote chemoresistance in gastric cancer. *Oncotarget*. 2017;8(29):47691–47708. doi:10.18632/oncotarget.8289

127. Xu N, Lian YJ, Dai X, et al. MiR-7 increases cisplatin sensitivity of gastric cancer cells through suppressing ubiquitin ligase expression. *Int J Oncol*. 2015;47(6):2769–2779. doi:10.3892/ijol.2015.2939

128. Huang H, Tang J, Zhang L, et al. MiR-874 regulates multidrug resistance of gastric cancer cells via targeting FBW7. *Oncol Lett*. 2017;14(5):6097–4026. doi:10.3892/ol.2018.9122

129. Fang Q, Chen X, Zhi X, Long non-coding RNA (LncRNA) urothelial carcinoma associated 1 (UCA1) increases multi-drug resistance of gastric cancer via downregulating miR-27b. *Med Sci Monit*. 2016;22:3506–3513. doi:10.12659/MSM.900688

130. Kim H, Choi H, Lee SK. Epstein-Barr virus miR-BART20-5p regulates cell proliferation and apoptosis by targeting BAD. *Cancer Lett*. 2015;358(2 Pt B):733–742. doi:10.1016/j.canlet.2014.10.023

131. Zhang Y, Liu C, Luo M, et al. Chemotherapy-induced miRNA-29c-catennin-6 signaling suppresses metastasis in gastric cancer. *Cancer Res*. 2015;75(7):1332–1344. doi:10.1158/0008-5472.CAN-14-0787

132. Zhang PF, Sheng LL, Wang G, et al. MiR-363 promotes proliferation and chemo-resistance of human gastric cancer via targeting FBW7 ubiquitin ligase expression. *Oncotarget*. 2016;7(23):233–248. doi:10.18632/oncotarget.7186

133. Zhang F, Li K, Yao X, et al. A miR-567-PK3AP1-PK3/CTC-myec feedback loop regulates tumour growth and chemoresistance in gastric cancer. *EBioMedicine*. 2019;44:311–321. doi:10.1016/j.ebiom.2019.05.003

134. Li N, Han M, Zhou N, et al. MicroRNA-495 confers increased sensitivity to chemotherapeutic agents in gastric cancer via the Mammalian Target of Rapamycin (mTOR) signaling pathway by interacting with human Epidermal Growth Factor Receptor 2 (ERBB2). *Med Sci Monit*. 2018;24:5960–5972. doi:10.12659/MSM.909458

135. Zhang W, Zhang L, Wang G, et al. MiR-363促进 proliferation and chemo-resistance of human gastric cancer via targeting FBW7 ubiquitin ligase expression. *Oncotarget*. 2016;7(23):35284–35292. doi:10.18632/oncotarget.9169

136. Wang H, Qin R, Guan A, et al. HOTAIR enhanced paclitaxel and doxorubicin resistance in gastric cancer cells partly through inhibiting miR-217 expression. *J Cell Biochem*. 2019;119(9):7226–7234. doi:10.1002/jcb.v119.9

137. Chang L, Gao F, Wang Y, et al. MicroRNA-200c regulates the sensitivity of chemotherapy to gastric cancer SGC7901/DPP cells by directly targeting RhoE. *Pathol Oncol Res*. 2014;20(1):93–98. doi:10.1007/s12533-013-9664-7

138. Nie H, Mu J, Wang J, et al. MiR-195-5p regulates multidrug resistance of gastric cancer cells via targeting ZNF139. *Oncol Rep*. 2018;40(3):1370–1378. doi:10.3892/or.2018.6524

139. Fang Q, Chen X, Zhi X, Long non-coding RNA (LncRNA) urothelial carcinoma associated 1 (UCA1) increases multi-drug resistance of gastric cancer via downregulating miR-27b. *Med Sci Monit*. 2016;22:3506–3513. doi:10.12659/MSM.900688

140. Wu DM, Hong XW, Wang LL, et al. MicroRNA-17 inhibition overcomes chemoresistance and suppresses epithelial-mesenchymal transition through a DEDD-dependent mechanism in gastric cancer. *Int J Biochem Cell Biol*. 2018;102:59–70. doi:10.1016/j.biocel.2018.06.007

141. Xia L, Zhang D, Du R, et al. MiR-15b and miR-16 modulate multidrug resistance by targeting BCL2 in human gastric cancer cells. *Int J Cancer*. 2008;123(2):372–379. doi:10.1002/ijc.23501

142. Xing Z, Yu L, Li X, et al. Anticancer bioactive peptide-3 inhibits human gastric cancer growth by targeting miR-338-5p. *Cell Biol*. 2016;6:53. doi:10.1186/s13578-016-0112-8

143. Zhao H, Zhao D, Tan G, et al. Bufalin promotes apoptosis of gastric cancer by down-regulation of miR-298 targeting bax. *Int J Clin Exp Pathol*. 2015;8(3):3420–3428.

144. You HY, Xie XM, Zhang WJ, et al. Berberine modulates cisplatin sensitivity of human gastric cancer cells by upregulation of miR-203. *In Vitro Cell Dev Biol Anim*. 2015;52(8):857–863. doi:10.1007/s11626-016-0044-y

145. Zhang W, Wang Y, Zhe Z, et al. Propofol inhibits proliferation, migration and invasion of gastric cancer cells by up-regulating microRNA-195. *Int J Biol Macromol*. 2018;120(Pt A):975–984. doi:10.1016/j.ijbiomac.2018.08.173

146. Zhang F, Ma C, Kaempferol suppresses human gastric cancer SNU-216 cell proliferation, promotes cell autophagy, but has no influence on cell apoptosis. *Braz J Med Biol Res*. 2019;52(2):e7843. doi:10.1590/1414-431x20187843

147. Xiang F, Pan C, Kong Q, et al. Ursolic acid inhibits the proliferation of gastric cancer cells by targeting miR-133a. *Oncol Rep*. 2014;32(5–6):267–273. doi:10.3892/ol.2014.3528

148. Shekari N, Javadian M, Ghasemi M, et al. Synergistic beneficial effect of docosahexaenoic acid (DHA) and docetaxel on the expression level of matrix metalloproteinase-2 (MMP-2) and microRNA-106b in gastric cancer. *J Gastrointest Cancer*. 2019. doi:10.1007/s12029-019-00205-0
157. Mohammadian F, Pilehvar SY, Mofarrah M, et al. Down regulation of miR-18a, miR-21 and miR-221 genes in gastric cancer cell line by chrysin-loaded PLGA-PEG nanoparticles. *Artif Cells Nanomed Biotechnol*. 2016;44(8):1972–1978. doi:10.3109/21691401.2015.1129615

158. Mohammadian F, Pilehvar SY, Alipour S, et al. Chrysin Alters microRNAs expression levels in gastric cancer cells: possible molecular mechanism. *Drug Res (Stuttg)*. 2017;67(9):509–514. doi:10.1055/s-0042-119647

159. Jia J, Zhan D, Li J, et al. The contrary functions of IncRNA HOTAIR/miR-17-5p/PTEN axis and Shenqifuzheng injection on chemosensitivity of gastric cancer cells. *J Cell Mol Med*. 2019;23(1):656–669. doi:10.1111/jcmm.13970

160. Zhu C, Huang Q, Zhu H. Melatonin inhibits the proliferation of gastric cancer cells through regulating the miR-16-5p-Smad3 pathway. *DNA Cell Biol*. 2018;37(3):244–252. doi:10.1089/dna.2017.4040